Canaccord Genuity Maintains a 'Buy' on Protalix BioTherapeutics (PLX); CMC Headline Risk May Not Impact Approvability
Tweet Send to a Friend
Canaccord Genuity maintains a 'Buy' rating on Protalix BioTherapeutics (NYSE Amex: PLX), lowers price target lowered to $10.
Canaccord analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
